Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges.

Szczegóły
Abstrakt

Tytuł:: Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges.
Autorzy:: Lustberg MB
Stover DG
Chalmers JJ
Źródło:: Cancer journal (Sudbury, Mass.) [Cancer J] 2018 Mar/Apr; Vol. 24 (2), pp. 61-64.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
Język:: English
Imprint Name(s):: Publication: 2007- : Sudbury, MA : Lippincott Williams & Wilkins
Original Publication: Sudbury, MA : Jones and Bartlett Publishers, c2000-
MeSH Terms:: Biomarkers, Tumor/*metabolism
Liquid Biopsy/*methods
Neoplasms/*metabolism
Neoplasms/*pathology
Clinical Trials as Topic ; Humans ; Precision Medicine/methods
References:: Clin Cancer Res. 2016 Feb 15;22(4):915-22. (PMID: 26459174)
Sci Transl Med. 2015 Aug 26;7(302):302ra133. (PMID: 26311728)
Clin Cancer Res. 2010 Feb 1;16(3):1073-84. (PMID: 20103672)
Biotechnol Bioeng. 2009 Feb 1;102(2):521-34. (PMID: 18726961)
Sci Transl Med. 2015 Nov 11;7(313):313ra182. (PMID: 26560360)
Clin Cancer Res. 2017 Oct 15;23(20):6305-6314. (PMID: 28710315)
C R Seances Soc Biol Fil. 1948 Feb;142(3-4):241-3. (PMID: 18875018)
Nat Biotechnol. 2008 Apr;26(4):400-1. (PMID: 18392022)
Mol Aspects Med. 2018 Apr;60:27-37. (PMID: 29155161)
Sci Transl Med. 2012 May 30;4(136):136ra68. (PMID: 22649089)
Clin Cancer Res. 2010 Nov 1;16(21):5233-43. (PMID: 20978147)
N Engl J Med. 2004 Aug 19;351(8):781-91. (PMID: 15317891)
Clin Cancer Res. 2008 Oct 1;14(19):6302-9. (PMID: 18829513)
Ann Oncol. 2009 Jul;20(7):1223-9. (PMID: 19282466)
Clin Cancer Res. 2002 Dec;8(12):3761-6. (PMID: 12473587)
EMBO Mol Med. 2014 Oct 30;6(11):1371-86. (PMID: 25358515)
Breast Cancer Res. 2014 Mar 06;16(2):R23. (PMID: 24602188)
Nat Rev Rheumatol. 2010 Jul;6(7):391-8. (PMID: 20517293)
Mol Oncol. 2015 Nov;9(9):1773-82. (PMID: 26093818)
N Engl J Med. 2013 Mar 28;368(13):1199-209. (PMID: 23484797)
Lung Cancer. 2012 Feb;75(2):242-7. (PMID: 21820198)
Clin Cancer Res. 2010 May 1;16(9):2634-45. (PMID: 20406831)
Nat Rev Cancer. 2011 Jun;11(6):426-37. (PMID: 21562580)
Nat Commun. 2017 Nov 6;8(1):1324. (PMID: 29109393)
Nature. 2013 May 2;497(7447):108-12. (PMID: 23563269)
Nat Rev Cancer. 2014 Sep;14(9):623-31. (PMID: 25154812)
Front Oncol. 2016 Nov 08;6:234. (PMID: 27878106)
Breast Cancer Res. 2014 Aug 09;16(4):421. (PMID: 25107527)
Mol Cancer Ther. 2017 Jul;16(7):1412-1420. (PMID: 28446639)
Cancer Discov. 2015 Oct;5(10):1040-8. (PMID: 26109333)
J Clin Oncol. 2016 Sep 1;34(25):2961-8. (PMID: 27269946)
Sci Transl Med. 2013 Jul 31;5(196):196cm6. (PMID: 23903752)
Cancer Res. 1977 Mar;37(3):646-50. (PMID: 837366)
JAMA Oncol. 2018 Jun 1;4(6):868-870. (PMID: 29242909)
Arch Otolaryngol Head Neck Surg. 2010 Dec;136(12):1274-9. (PMID: 21173379)
Cancer Treat Rev. 2011 Dec;37(8):579-89. (PMID: 21592671)
Prostate Cancer Prostatic Dis. 2000 Jul;3(1):21-27. (PMID: 12497157)
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8. (PMID: 15194824)
Clin Cancer Res. 2012 Jun 15;18(12):3462-9. (PMID: 22421194)
Ann Oncol. 2014 Oct;25(10):1959-1965. (PMID: 25185240)
Methods Mol Biol. 2016;1379:45-68. (PMID: 26608289)
Front Oncol. 2012 Oct 25;2:128. (PMID: 23112954)
Cancer Discov. 2016 Aug;6(8):838-851. (PMID: 27179038)
N Engl J Med. 2014 Sep 11;371(11):1028-38. (PMID: 25184630)
J Clin Oncol. 2014 Nov 1;32(31):3483-9. (PMID: 24888818)
Clin Cancer Res. 2008 Apr 1;14(7):1938-46. (PMID: 18381931)
Front Mol Biosci. 2017 Nov 28;4:79. (PMID: 29234666)
Nat Commun. 2015 Nov 04;6:8760. (PMID: 26530965)
Nat Med. 2008 Sep;14(9):985-90. (PMID: 18670422)
Methods Mol Biol. 2017;1634:219-234. (PMID: 28819855)
BMC Cancer. 2016 Sep 22;16(1):744. (PMID: 27658492)
Clin Cancer Res. 2010 Mar 15;16(6):1745-55. (PMID: 20215558)
Ann Oncol. 2018 Jan 1;29(1):193-199. (PMID: 29361135)
Grant Information:: P30 CA016058 United States CA NCI NIH HHS; R01 CA097391 United States CA NCI NIH HHS; R01 HL131720 United States HL NHLBI NIH HHS
Substance Nomenclature:: 0 (Biomarkers, Tumor)
Entry Date(s):: Date Created: 20180331 Date Completed: 20190321 Latest Revision: 20240314
Update Code:: 20240314
PubMed Central ID:: PMC5880324
DOI:: 10.1097/PPO.0000000000000309
PMID:: 29601331
: Czasopismo naukowe

A primary goal of personalized medicine is to develop tumor-specific biomarkers to aid in treatment selection and to better evaluate response to targeted therapies. The assessment of circulating blood markers as surrogate real-time biopsies of disease status, termed liquid biopsies, has been under investigation. There are many different types of liquid biopsies each with different functionalities and limitations. These include tumor markers, circulating tumor cells, cell-free DNA, and extracellular vesicles including exosomes. Multiple clinical trials have evaluated liquid biopsies as prognostic biomarkers with positive results. Additional studies are underway to evaluate liquid biopsies as predictive biomarkers, pharmacodynamic biomarkers, and surrogate efficacy endpoints for treatment response evaluation. There are several challenges in and barriers to implementation of liquid biopsies into clinical trials and subsequently into routine clinical practice, which are addressed in this review.

Informacja